Lineage Cell Therapeutics, Inc.
LCTX
$1.61
$0.031.90%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.56M | 10.82M | 10.91M | 9.56M | 9.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.56M | 10.82M | 10.91M | 9.56M | 9.50M |
| Cost of Revenue | 6.52M | 6.63M | 6.66M | 6.43M | 6.41M |
| Gross Profit | 8.04M | 4.18M | 4.25M | 3.13M | 3.09M |
| SG&A Expenses | 18.46M | 18.01M | 18.23M | 18.03M | 18.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.34M | 31.16M | 31.31M | 30.88M | 30.98M |
| Operating Income | -21.78M | -20.34M | -20.40M | -21.32M | -21.48M |
| Income Before Tax | -68.65M | -67.51M | -40.76M | -16.17M | -18.58M |
| Income Tax Expenses | -5.28M | -- | -- | -- | -- |
| Earnings from Continuing Operations | -63.37 | -67.51 | -40.76 | -16.17 | -18.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -166.00K | -148.00K | -152.00K | -39.00K | -27.00K |
| Net Income | -63.53M | -67.66M | -40.91M | -16.21M | -18.61M |
| EBIT | -21.78M | -20.34M | -20.40M | -21.32M | -21.48M |
| EBITDA | -21.08M | -19.68M | -19.77M | -20.72M | -20.87M |
| EPS Basic | -0.28 | -0.30 | -0.18 | -0.08 | -0.10 |
| Normalized Basic EPS | -0.15 | -0.14 | -0.07 | -0.05 | -0.06 |
| EPS Diluted | -0.28 | -0.30 | -0.18 | -0.08 | -0.10 |
| Normalized Diluted EPS | -0.15 | -0.14 | -0.07 | -0.05 | -0.06 |
| Average Basic Shares Outstanding | 920.43M | 923.46M | 883.44M | 843.89M | 800.75M |
| Average Diluted Shares Outstanding | 920.43M | 923.46M | 883.44M | 843.89M | 800.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |